Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: valent j. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH. Bhutani D, et al. Among authors: valent j. Support Care Cancer. 2013 Sep;21(9):2437-42. doi: 10.1007/s00520-013-1808-5. Epub 2013 Apr 17. Support Care Cancer. 2013. PMID: 23591714 Free PMC article.
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Usmani SZ, et al. Among authors: valent j. Blood Cancer J. 2015 Aug 7;5(8):e334. doi: 10.1038/bcj.2015.62. Blood Cancer J. 2015. PMID: 26252787 Free PMC article. No abstract available.
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD Jr, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S. Chari A, et al. Among authors: valent j. Leuk Lymphoma. 2018 Nov;59(11):2588-2594. doi: 10.1080/10428194.2018.1443337. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616843 Clinical Trial.
Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Khouri J, et al. Among authors: valent j. Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938774 Free article. No abstract available.
64 results